2-(3-Bromophenyl)histamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-Bromophenyl)histamine
• 英文别名: 2-[2-(3-bromophenyl)-1H-imidazol-5-yl]ethanamine
• 化学式: C₁₁H₁₂BrN₃
• 分子量: 266.14
• InChiKey: VSKJPAMQPJDPLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-溴苯甲亚氨酸甲酯盐酸盐 在 盐酸 、 氨 作用下， 反应 30.0h， 生成 2-(3-Bromophenyl)histamine
  参考文献：
  名称：

  2-Alkyl-substituted histamines and hydroxyethylimidazoles with G-protein-stimulatory activity

  摘要：

  Cationic-amphiphilic 2-substituted histamines activate pertussis toxin-sensitive guanine nucleotide-binding proteins (G-proteins) by a receptor-independent mechanism. From our recent studies it became apparent that lipophilicity is an important determinant for this G-protein activation, but the influence of basicity remained unknown. We prepared seven novel 2-alkyl-substituted histamines and five novel 2-alkyl-substituted hydroxyethylimidazoles and studied their effects on high-affinity guanosine triphosphate (GTP) hydrolysis in membranes of the human leukemia cell line, HL-60. 2-Octylhistamine was found to be the most effective GTPase activator among 2-substituted histamines presently available (150% stimulation above basal), and 2-tetradecylhistamine is the most potent substance in this regard (pEC(50) = 5.9). Branching of the alkyl chain and the introduction of an ether group adversely affected GTPase activation. Compared to a phenyl ring, a bulky adamantyl sphere enhanced G-protein-stimulatory activity. In the case of 2-(3-bromophenyl)histamine, 2-adamantylhistamine and 2-(3-phenylpropyl)histamine, replacement of the aminoethyl group by a hydroxyethyl group at the imidazole greatly reduced GTPase-activating properties, pointing to the importance of the basic domain in the activation process. Unexpectedly, however, in the case of a very lipophilic substituent (heptadecyl chain) the exchange of the aminoethyl group by a hydroxyethyl group had no substantial inhibitory effect, indicating that the presence of a primary amine is not a conditio sine qua non for a substance being a receptor-independent G-protein activator. Concerning histamine H-1-receptors the newly prepared compounds proved to be weak antagonists.

  DOI：

  10.1016/0223-5234(96)89166-5

文献信息

• Synthesis and Histamine H1 Receptor Agonist Activity of a Series of 2-Phenylhistamines, 2-Heteroarylhistamines, and Analogs
  作者：Christian Leschke、Sigurd Elz、Monique Garbarg、Walter Schunack

  DOI：10.1021/jm00008a007

  日期：1995.4

  2-phenylhistamines (halogen = Br (35) and I (36)) were equipotent with histamine, while 2-(3-(trifluoromethyl)phenyl)histamine (2-[2-(3-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]ethanamine (39)) was significantly more potent than histamine (39: pD2 = 6.81, relative activity = 128%). The 2-substituted histamine analogues were partial H1 receptor agonists on the endothelium-denuded isolated guinea pig aorta with

  分别由合适的酰亚胺或am和乙酸2-氧代-4-邻苯二甲酰亚胺基-1-丁酸酯制备了新的组胺衍生物，其特征是在咪唑环的C2位上有一个（取代的）芳基，杂芳基，苄基或杂芳基甲基取代基（1）。在分离的豚鼠回肠上筛选化合物作为潜在的H1受体激动剂。3-卤代2-苯基组胺（卤素= Br（35）和I（36））与组胺等价，而2-（3-（三氟甲基）苯基）组胺（2- [2-（3-（三氟甲基）苯基）-1H-咪唑-4-基乙乙胺（39）比组胺的效价明显更高（39：pD2 = 6.81，相对活性= 128％）。2-取代的组胺类似物是内皮剥脱的豚鼠主动脉上的部分H1受体激动剂，pEC50值通常小于豚鼠回肠上观察到的，但发现效价等级顺序相似。H1受体拮抗剂美吡拉明可以分别依赖浓度地阻断对豚鼠回肠和主动脉的收缩作用，从而产生美吡拉敏的KB值在纳摩尔范围内。体外化合物35和39与[3H]美吡拉敏标记的豚鼠小脑膜结合，pKi分别为6
• METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20160000777A1

  公开（公告）日：2016-01-07

  This invention relates to a transdermal drug formulation that includes a pharmaceutically suitable carrier; an effective amount of a therapeutic agent; and a histamine type 4 receptor (“H4R”) agonist, as well as a transdermal vaccine formulation that includes a pharmaceutically suitable carrier; an effective amount of an antigen or antigen-encoding nucleic acid molecule present in the carrier, and optionally one or more adjuvants; and an H4R agonist. The present invention also relates to transdermal delivery device including such formulations and methods of administering such formulations. The present invention also relates to methods of enhancing epithelial barrier formation in a patient involving administering to the patient at a site of epithelial disruption an amount of a formulation that comprises an H4R antagonist. The present invention also relates to a method of inhibiting pathogen infection or local spread of infection in the epithelia using an H4R antagonist, an H1R antagonist, or a combination thereof.
• [EN] METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS<br/>[FR] MÉTHODES D'UTILISATION D'AGONISTES ET D'ANTAGONISTES DU RÉCEPTEUR DE L'HISTAMINE
  申请人：UNIV ROCHESTER

  公开号：WO2014130759A1

  公开（公告）日：2014-08-28

  This invention relates to a transdermal drug formulation that includes a pharmaceutically suitable carrier; an effective amount of a therapeutic agent; and a histamine type 4 receptor ("H4R") agonist, as well as a transdermal vaccine formulation that includes a pharmaceutically suitable carrier; an effective amount of an antigen or antigen-encoding nucleic acid molecule present in the carrier, and optionally one or more adjuvants; and an H4R agonist. The present invention also relates to transdermal delivery device including such formulations and methods of administering such formulations. The present invention also relates to methods of enhancing epithelial barrier formation in a patient involving administering to the patient at a site of epithelial disruption an amount of a formulation that comprises an H4R antagonist. The present invention also relates to a method of inhibiting pathogen infection or local spread of infection in the epithelia using an H4R antagonist, an H1R antagonist, or a combination thereof.